There are 2867 resources available
957P - Proton-therapy and concurrent chemotherapy in stage III NSCLC: Effects on toxicity and immune therapy
Presenter: Francesco Cortiula
Session: Poster session 04
958P - Intensity-modulated radiotherapy (IMRT)-adapted chemoradiotherapy (CRT) followed by durvalumab for locally advanced non-small cell lung cancer (NSCLC): A multicenter prospective observational study (WJOG12019L)
Presenter: Nobuaki Mamesaya
Session: Poster session 04
959P - The association of GTV and brain metastasis development in patients with stage III NSCLC
Presenter: Haiyan Zeng
Session: Poster session 04
960P - Beyond PACIFIC: Real-world outcomes of adjuvant durvalumab according to treatment received and PD-L1 expression
Presenter: Marie-Hélène Denault
Session: Poster session 04
962P - Quality of life at diagnosis for unresectable stage III NSCLC: Initial results from the national prospective study OBSTINATE (GFPC 06-2019)
Presenter: Charles Ricordel
Session: Poster session 04
963P - Clinical research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): Real-world evidence of NSCLC patients treated with radiochemotherapy in Germany – AIO-TRK-0315
Presenter: Wilfried Eberhardt
Session: Poster session 04
964P - PACIFIC on the West Coast: Exploring reasons for not receiving consolidative durvalumab in the treatment of locally advanced lung cancer
Presenter: Jamie Feng
Session: Poster session 04
965P - Real-world toxicity of consolidation durvalumab following chemoradiotherapy (CRT) in elderly and comorbid patients (pts) with unresectable stage III NSCLC: A multi-centre, Australian experience
Presenter: Samuel Stevens
Session: Poster session 04
966P - Evaluation of the prognostic marker of PD-L1 expression after combined radio-chemotherapy in patients with non-small cell lung cancer (NSCLC) stage III
Presenter: Kay Willborn
Session: Poster session 04